Menu
Recruiting NCT07546812

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Phase II Interventional HER2-negative Gastroesophageal Junction Esophageal Adenocarcinoma Gastric Adenocarcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Denikitug, Nivolumab, Ramucirumab, Paclitaxel.
Who it may be relevant to
Registry conditions: HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Australia
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Overview

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based combinations in in participants with human epidermal growth factor receptor 2 (HER2)-Negative, unresectable, recurrent, and/or metastatic, gastroesophageal junction (GEJ), and esophageal adenocarcinomas. The primary objective of this study is to assess the effect of DEN as a monotherapy or in combination with nivolumab (NIVO) or ramucirumab (RAM) and paclitaxel (PAC) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version1.1).

Interventions

  • Drug Denikitug
    Administered Intravenously
  • Drug Nivolumab
    Administered Intravenously
  • Drug Ramucirumab
    Administered Intravenously
  • Drug Paclitaxel
    Administered Intravenously

Primary outcome measures

  • Objective Response Rate (ORR) [Time frame: Up to 4 years]
Secondary outcome measures (9)
  • Duration of Response (DOR) [Time frame: Up to 4 years]
  • Progression-Free Survival (PFS) [Time frame: Up to 4 years]
  • Overall Survival (OS) [Time frame: Up to 4 years]
  • Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [Time frame: First dose date up to 120 days post last dose, up to 4 years.]
  • Percentage of Participants Experiencing Clinical Laboratory Abnormalities According to the NCI CTCAE v5.0 [Time frame: First dose date up to 120 days post last dose, up to 4 years.]
  • Pharmacokinetic (PK) Parameter: Serum concentration of DEN [Time frame: Up to 4 years]
  • PK Parameter: Cmax for Denikitug [Time frame: Up to 4 years]
  • PK Parameter: AUCall for Denikitug [Time frame: Up to 4 years]
  • Percentage of Participants who Developed Treatment-Emergent Antidrug Antibody (ADA) Against Denikitug [Time frame: Up to 4 years]

Eligibility criteria

Inclusion criteria

  • Histologically or cytologically confirmed diagnosis of locally advanced, unresectable, or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC).
  • Human epidermal growth factor receptor 2 (HER2)-negative status, as determined by local assessment using a validated immunohistochemistry assay, in situ hybridization or other amplification testing.
  • Has had disease progression during or after first line of systemic therapy for advanced or metastatic gastric, GEJ, or EACs, which must have included at least one of the following:
  • Platinum- and fluoropyrimidine-based chemotherapy.
  • Therapy with an anti-programmed cell death protein 1 (PD1) or anti-programmed cell death ligand 1 (anti-PD-L1) monoclonal antibody (patients with PD-L1-positive tumors must have received prior PD-1/PD-L1-based therapy).
  • Zolbetuximab or other Claudin-18 (CLDN18).2-targeted therapy, if indicated based on biomarker status.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • Have adequate organ function.
  • Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use methods of contraception.

Exclusion criteria

  • Active or history of autoimmune disease requiring systemic treatment within 2 years, inflammatory bowel disease (IBD) (Crohn's/ulcerative colitis), celiac disease, or noninfectious enteritis/colitis. (Physiologic hormone replacement not considered systemic treatment).
  • History or current noninfectious pneumonitis/interstitial lung disease, including radiation-induced pneumonitis requiring steroids or active/recurrent pneumonitis of any etiology.
  • Documented microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) disease by local polymerase chain reaction (PCR) (microsatellite status) and/or informed consent form (ICH) (mismatch repair (MMR)) assay
  • (For Part 2 only) Has known history of peripheral neuropathy ≥ Grade 2 (per National Cancer Institute(NCI)-Common Tenninology Criteria for Adverse Events (CTCAE) Version 5.0).
  • (For Part 2 only) Known coagulopathy that increases the risk of bleeding, bleeding diatheses. Any other Grade 3 or higher hemorrhage/bleeding event within 28 days prior to enrollment.

Prior/Concurrent Therapy or Clinical Study Experience

  • Prior treatment with DEN or other C-C chemokine receptor 8 (CCR8)-targeted agents.
  • Prior Lonsurf (trifluridine-tipiracil) or paclitaxel (PAC)-based regimens in the first-line setting for advanced/metastatic gastroesophageal adenocarcinoma.
  • Any systemic therapy (including investigational) targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGFR) signaling pathways.
  • Anticancer biologic within 4 weeks, orchemotherapy, targeted small molecule, or radiation therapy within 2 weeks prior to enrollment with unresolved adverse events (AE)s (Grade >2). (Observational study participants are eligible).
  • Prior allogenic tissue/solid organ or stem cell transplantation. (Exception: corneal transplant not requiring systemic immunosuppression is allowed).

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Australia · 3 centers
  • Chris O'Brien Lifehouse — Camperdown
  • Royal Brisbane and Women's Hospital — Herston
  • Hollywood Private Hospital — Nedlands
United States · 1 center
  • Massachusetts General Hospital — Boston

Identifiers

NCT: NCT07546812 · GS-US-742-7757 · 2025-524095-27

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗